Abstract:The Ankaferd Blood Stopper (ABS) proves effective in managing various bleedings, particularly in surgical and dental procedures. This study assesses ABS efficacy endoscopically by less-experienced endoscopists for non-variceal upper gastrointestinal bleeding (NVUGB). Between 2016 and 2021, our hospital's Gastroenterology Department Endoscopy Unit conducted a retrospective data analysis of 653 patients who underwent endoscopy for NVUGB. The study included 202 patients who underwent endoscopic interventions performed by endoscopists with less than 3 years of experience. Based on the method used for endoscopic hemostasis, we classified those treated with ABS (either alone or as a second method) as group 1. In contrast, we classified patients treated with non-ABS hemostatic methods into Group 2. The study included 202 patients, with 96 (47.52%) in Group 1 and 106 (52.48%) in Group 2. All patients in Group 1 achieved bleeding control, while 4 patients in Group 2 initially did not achieve bleeding control; however, bleeding control was subsequently established following ABS administration. After 1 month of follow-up, mortality occurred in 3 out of 202 patients (1.48%), and all these cases were in Group 2. There is a significant difference in the need for blood transfusion between the groups (P < .001). Regarding the bleeding source, bulbus ulcer and gastric cancer were more prevalent in Group 2. On the other hand, although statistical significance was not reached in the comparison of rebleeding rates between groups, numerically, a higher incidence of recurrent bleeding was observed in Group 2 (Group 1: 3 [3.1%], Group 2: 8 [7.5%]; P = .167). Additionally, a similar relationship was noted among intensive care admissions (Group 1: 5 [5.2%]; Group 2: 7 [6.6%]; P = .675). In the group that used ABS, there were significantly higher rates of hypotension, tachycardia, syncope, and the need for transfusion than in the other group. In medical practice, this distinction often stems from the shared preference of clinicians to use ABS as a salvage method in cases of more severe bleeding. Considering all the findings, it is evident that using ABS through endoscopy in cases of NVUGIB significantly improves procedural success, irrespective of the endoscopist's experience level.

New Coagulant Agent (Ankaferd Blood Stopper) for Open Hemorrhages in Hemophilia With Inhibitor

PRO53 CLOTTING FACTOR UTILIZATION AND BLEEDING RATES AMONG PERSONS WITH HEMOPHILIA A FROM A LONGITUDINAL STUDY

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies

Ankaferd blood stopper: A novel additional strategy for less experienced gastroenterologists in gastrointestinal bleeding treatment

Inhibitor Eradication and Bleeding Management of Acquired Hemophilia A: a Single Center Experience in China

Generation of Chimeric “ABS Nanohemostat” Complex and Comparing Its Histomorphological In Vivo Effects to the Traditional Ankaferd Hemostat in Controlled Experimental Partial Nephrectomy Model

Non-factor Therapies for Hemophilia: Achievements and Perspectives

Efficacy and Safety of Third-Generation Full Length Recombinant Human Coagulation Factor VIII in the Standard Prophylactic Treatment of Childhood Patients with Moderate-to-Severe Hemophilia A: A Single Center Experience

Determination of the Effects of Ankaferd Wound Dressing on the Wound Healing Process in Rats

Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol

Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment

A treatment bridge for infants with hemophilia

Ankaferd blood stopper enhances healing after osseous grafting in patients with intrabony periodontal defects

S3808 Hemostatic Peptides: An Effective Tool for Managing Bleeding When Traditional Options Are Challenging

Perioperative Management for Port Catheter Procedures in Pediatric Patients with Severe Hemophilia and Inhibitors

Comparison Pharmacokinetic Dosing Tools in Hemophilia A Children

Targeted Inhibition of Activated Protein C by a Non-Active-site Inhibitory Antibody to Treat Hemophilia

A creative approach to managing a case of haemophilia A with inhibitors in a low-resource country: case report

Phase 4 Safety and Efficacy Study of Antihemophilic Factor (recombinant) in Previously Treated Chinese Patients with Severe/Moderately Severe Hemophilia A.

Pharmacokinetic Parameter Driven Outcomes Model Predicts a Reduction in Bleeding Events Associated with BAY 81–8973 Versus Antihemophilic Factor (recombinant) Plasma/albumin-Free Method in a Chinese Healthcare Setting

Effects of Algan hemostatic agent foam in rat femoral artery injury model: A randomized animal trial